New heart mapping tech could improve AFib treatment safety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject must provide written informed consent prior to any clinical investigation-related procedure. 2. Subject is at least 18 years of age. 3. Documented symptomatic paroxysmal AF, defined as: * Physician's note indicating self-terminating AF AND * Electrocardiographically documented AF NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device. 4. Subject plans to undergo a cardiac electroanatomic mapping and ablation procedure to treat their paroxysmal AF. 5. Able and willing to comply with all trial requirements including pre-procedure, post-procedure, and follow-up testing and requirements Exclusion Criteria: 1. Primary diagnosis or indication for treatment of persistent or long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration) 2. Known presence of cardiac thrombus. 3. Known existing circumferential pericardial effusion \>2 mm prior to catheter insertion. 4. Presence of any condition that precludes appropriate vascular access 5. Implanted intracardiac device within 30 days prior to the procedure 6. Pregnant or nursing 7. Patients who have had a ventriculotomy or atriotomy within 28 days prior to the procedure 8. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days 9. Stroke or TIA (transient ischemic attack) within the last 90 days 10. History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant state 11. Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation 12. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication 13. Previous left atrial surgical procedure (including left atrial appendage (LAA) closure device) 14. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2) 15. Previous tricuspid or mitral valve replacement or repair 16. Patients with prosthetic valves 17. Patients with a myxoma 18. Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt 19. Stent, constriction, or stenosis in a pulmonary vein 20. Rheumatic heart disease 21. Hypertrophic cardiomyopathy 22. Active systemic infection 23. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms 24. Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from this study Sponsor 25. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results. 26. Individuals without legal authority 27. Individuals unable to read or write